Compare Alcon AG (ALC) vs Celestica Inc (CLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Celestica Inc — how do they compare? Alcon AG trades at $66.9 (market cap $32.69B), while Celestica Inc trades at $353 (market cap $39.70B). The key difference: Celestica Inc is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| ALC | CLS | |
|---|---|---|
Market Cap | $32.69B | $39.70B |
Sector | Health | Technology |
52-Week High | $92.22 | $472.40 |
52-Week Low | $62.02 | $155.70 |
Enterprise Value | $36.28B | $40.10B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Celestica (CLS) trades at $350.20, up 4.16% over 24 hours, with a bearish technical signal and neutral oscillators. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and robust profitability metrics, including a 52.45% ROE. Recent leadership appointments in cloud solutions and positive analyst coverage highlight growth potential amid competitive pressures.
The stock presents a compelling growth opportunity with a consensus price target of $440.10, implying 25% upside, supported by AI and data center demand. Key risks include margin pressures, technical bearish signals, and reliance on execution amid industry competition. Investors should weigh strong earnings trajectory against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
